Skip to main content
Top
Published in: Medical Oncology 1/2013

01-03-2013 | Original Paper

Analysis of the clinico-hematological relevance of the breakpoint location within M-BCR in chronic myeloid leukemia

Authors: Ayda Bennour, Ines Ouahchi, Bechir Achour, Monia Zaier, Yosra Ben Youssef, Abderrahim Khelif, Ali Saad, Halima Sennana

Published in: Medical Oncology | Issue 1/2013

Login to get access

Abstract

The Philadelphia chromosome (Ph) derives from the balanced translocation between chromosomes 9 and 22. This chromosomal translocation results in the fusion between the 5′ part of the BCR gene, normally located on chromosome 22, and the 3′ part of the ABL gene on chromosome 9 giving origin to a BCR-ABL fusion gene which is transcribed and then translated into a hybrid protein. In general, three breakpoint cluster regions in the BCR gene have been described: major (M-BCR), minor (m-BCR) and micro (μ-BCR). Three main variants of the BCR-ABL gene have been described depending on the length of the sequence of the BCR gene included that encode for the P190, P210, P230 proteins. Most patients (95 %) were found to have P210 protein that resulted from rearrangement in the M-BCR region in the BCR gene and thus gives rise to b2a2 or b3a2 variants. The incidence of one or other rearrangement in chronic myeloid leukemia (CML) patients varies in different reported series. These two variants are associated with distinct clinical types of human leukemias. In this study, we report the frequencies of M-BCR-ABL fusion transcripts in 44 CML patients and we review the data on the correlations between the type of M-BCR/ABL variant and the corresponding sex, age and biological features. Forty-four untreated chronic phase CML patients were studied. The type of BCR-ABL fusion transcripts was determined by reverse transcriptase polymerase chain reaction (RT-PCR). More than half of them showed b3a2 fusion transcript (64 %), while (36 %) showed b2a2 transcript. No patients coexpressed b3a2/b2a2. Correlation between biological data demonstrated that: (a) M-BCR rearrangements were not associated with the sex of the patients. (b) Patients with b3a2 rearrangements were older than patients with b2a2 transcripts. (c) M-BCR rearrangements were influenced neither by the white blood count (WBC) nor with hemoglobin levels. However, platelet level is more elevated in patients with b3a2 transcript (681.2/L vs. 207/L; P = 0.001). In conclusion, we observed significant correlations between age, platelet level and M-BCR-ABL transcript, these observations deserve further investigations.
Literature
1.
go back to reference Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290–3.PubMedCrossRef Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290–3.PubMedCrossRef
2.
go back to reference Léglise MCH, Pluchon-Rivière E, Calvez JF G Le, Berthou CH, Autrand C, Luc Sensebè DB, Balcon D, Le Roux AM. Molecular diagnosis and follow-up in myeloproliferative syndromes and acute leukemias: correlation between expression of fusion transcripts and disease progression in chronic myeloid leukemia. Leuk Lymphoma. 1996;21:187–99.PubMedCrossRef Léglise MCH, Pluchon-Rivière E, Calvez JF G Le, Berthou CH, Autrand C, Luc Sensebè DB, Balcon D, Le Roux AM. Molecular diagnosis and follow-up in myeloproliferative syndromes and acute leukemias: correlation between expression of fusion transcripts and disease progression in chronic myeloid leukemia. Leuk Lymphoma. 1996;21:187–99.PubMedCrossRef
3.
go back to reference Crist W, Carrol A, Shuster J, Jackson J, Head D, Borowitz M, Behm F, Link M, Steuber P, Ragab A, et al. Philadelphia chromosome-positive childhood acute lymphoblastic leukemia: clinical and cytogenetic characteristics and treatment outcome: a Pediatric Oncology Group (POG) study. Blood. 1990;76:489–94.PubMed Crist W, Carrol A, Shuster J, Jackson J, Head D, Borowitz M, Behm F, Link M, Steuber P, Ragab A, et al. Philadelphia chromosome-positive childhood acute lymphoblastic leukemia: clinical and cytogenetic characteristics and treatment outcome: a Pediatric Oncology Group (POG) study. Blood. 1990;76:489–94.PubMed
4.
go back to reference Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 1984;36:93–9.PubMedCrossRef Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 1984;36:93–9.PubMedCrossRef
5.
go back to reference Quintás-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood. 2009;113:1619–30.PubMedCrossRef Quintás-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood. 2009;113:1619–30.PubMedCrossRef
6.
go back to reference Paz-y-Mino C, Burgos R, Morillo SA, Santos JC, Fiallo BF, Leone PE. BCR-ABL rearrangement frequencies in chronic myeloid leukemia and acute lymphoblastic leukemia in Ecuador South America. Cancer Genet Cytogenet. 2002;132:65–7.PubMedCrossRef Paz-y-Mino C, Burgos R, Morillo SA, Santos JC, Fiallo BF, Leone PE. BCR-ABL rearrangement frequencies in chronic myeloid leukemia and acute lymphoblastic leukemia in Ecuador South America. Cancer Genet Cytogenet. 2002;132:65–7.PubMedCrossRef
7.
go back to reference Osman EA, Hamad K, Fadl Elmula IM, Ibrahim ME, et al. Frequencies of BCR-ABL1 fusion transcripts among Sudanese chronic myeloid leukaemia patients. Genet Mol Biol. 2010;33:229–31.PubMedCrossRef Osman EA, Hamad K, Fadl Elmula IM, Ibrahim ME, et al. Frequencies of BCR-ABL1 fusion transcripts among Sudanese chronic myeloid leukaemia patients. Genet Mol Biol. 2010;33:229–31.PubMedCrossRef
8.
go back to reference Van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukaemia for detection of minimal residual disease. Report of the BIOMOED-1 concerted action: investigation of minimal residual disease in acute leukaemia. Leukemia. 1999;13:1901–28.PubMedCrossRef Van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukaemia for detection of minimal residual disease. Report of the BIOMOED-1 concerted action: investigation of minimal residual disease in acute leukaemia. Leukemia. 1999;13:1901–28.PubMedCrossRef
9.
go back to reference Pane F, Frigeri F, Sindona M, Luciano L, Ferrara F, Cimino R, et al. Neutrophilic chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR-ABL with C3/A2 junction). Blood. 1996;88:2410–4.PubMed Pane F, Frigeri F, Sindona M, Luciano L, Ferrara F, Cimino R, et al. Neutrophilic chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR-ABL with C3/A2 junction). Blood. 1996;88:2410–4.PubMed
10.
go back to reference Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343–56.PubMed Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343–56.PubMed
11.
go back to reference Selleri L, von Lindem M, Hermans A, Meijer D, Torelli G, Grosveld G. Chronic myeloid leukemia may be associated with several bcr-ab1 transcripts including the acute lymphoid leukemia-type 7 kb transcript. Blood. 1990;75:1146.PubMed Selleri L, von Lindem M, Hermans A, Meijer D, Torelli G, Grosveld G. Chronic myeloid leukemia may be associated with several bcr-ab1 transcripts including the acute lymphoid leukemia-type 7 kb transcript. Blood. 1990;75:1146.PubMed
13.
go back to reference Goldman JM, Druker BJ. Chronic myeloid leukemia: current treatment options. Blood. 2001;1(98):2039–42.CrossRef Goldman JM, Druker BJ. Chronic myeloid leukemia: current treatment options. Blood. 2001;1(98):2039–42.CrossRef
14.
go back to reference De Lemos JA, de Oliveira CM, Scerni AC, et al. Differential molecular response of the transcripts B2A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia. Genet Mol Res. 2005;4:803–11.PubMed De Lemos JA, de Oliveira CM, Scerni AC, et al. Differential molecular response of the transcripts B2A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia. Genet Mol Res. 2005;4:803–11.PubMed
15.
go back to reference Lucas CM, Harris RJ, Giannoudis A, et al. Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. Haematologica. 2009;94:1362–7.PubMedCrossRef Lucas CM, Harris RJ, Giannoudis A, et al. Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. Haematologica. 2009;94:1362–7.PubMedCrossRef
16.
go back to reference Sharma P, Kumar L, Mohanty S, Kochupillai V. Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts. Ann Hematol. 2010;89:241–7.PubMedCrossRef Sharma P, Kumar L, Mohanty S, Kochupillai V. Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts. Ann Hematol. 2010;89:241–7.PubMedCrossRef
17.
go back to reference Mondal BC, Bandyopadhyay A, Majumdar S, et al. Molecular profiling of chronic myeloid leukemia in eastern India. Am J Hematol. 2006;81:845–9.PubMedCrossRef Mondal BC, Bandyopadhyay A, Majumdar S, et al. Molecular profiling of chronic myeloid leukemia in eastern India. Am J Hematol. 2006;81:845–9.PubMedCrossRef
18.
go back to reference Adler R, Viehmann S, Kuhlisch E, et al. Correlation of BCR/ABL transcript variants with patients’ characteristics in childhood chronic myeloid leukaemia. Eur J Haematol. 2009;82:112–8.PubMedCrossRef Adler R, Viehmann S, Kuhlisch E, et al. Correlation of BCR/ABL transcript variants with patients’ characteristics in childhood chronic myeloid leukaemia. Eur J Haematol. 2009;82:112–8.PubMedCrossRef
19.
go back to reference Inokuchi K, Inoue T, Tojo A, et al. A possible correlation between the type of bcr-abl hybrid messenger RNA and platelet count in Philadelphia-positive chronic myelogenous leukemia. Blood. 1991;78:3125–7.PubMed Inokuchi K, Inoue T, Tojo A, et al. A possible correlation between the type of bcr-abl hybrid messenger RNA and platelet count in Philadelphia-positive chronic myelogenous leukemia. Blood. 1991;78:3125–7.PubMed
20.
go back to reference Perego RA, Costantini M, Cornacchini G, et al. The possible influences of B2A2 and B3A2 BCR/ABL protein structure on thrombopoiesis in chronic myeloid leukaemia. Eur J Cancer. 2000;36:1395–401.PubMedCrossRef Perego RA, Costantini M, Cornacchini G, et al. The possible influences of B2A2 and B3A2 BCR/ABL protein structure on thrombopoiesis in chronic myeloid leukaemia. Eur J Cancer. 2000;36:1395–401.PubMedCrossRef
21.
go back to reference Verschraegen CF, Kantarjian HM, Hirsch-Ginsberg C, et al. The breakpoint cluster region site in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Clinical, laboratory, and prognostic correlations. Cancer. 1995;76:992–7.PubMedCrossRef Verschraegen CF, Kantarjian HM, Hirsch-Ginsberg C, et al. The breakpoint cluster region site in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Clinical, laboratory, and prognostic correlations. Cancer. 1995;76:992–7.PubMedCrossRef
22.
go back to reference Rozman C, Urbano-Ispizua A, Cervantes F, et al. Analysis of the clinical relevance of the breakpoint location within M-BCR and the type of chimeric mRNA in chronic myelogenous leukemia. Leukemia. 1995;9:1104–7.PubMed Rozman C, Urbano-Ispizua A, Cervantes F, et al. Analysis of the clinical relevance of the breakpoint location within M-BCR and the type of chimeric mRNA in chronic myelogenous leukemia. Leukemia. 1995;9:1104–7.PubMed
23.
go back to reference Opalka B, Wandl UB, Kloke O, et al. No correlation between site of breakpoint in the BCR gene and platelet counts in Philadelphia chromosome-positive CML. Leuk Res. 1992;16:937–9.PubMedCrossRef Opalka B, Wandl UB, Kloke O, et al. No correlation between site of breakpoint in the BCR gene and platelet counts in Philadelphia chromosome-positive CML. Leuk Res. 1992;16:937–9.PubMedCrossRef
24.
go back to reference Melo J. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 1996;88:2375–84.PubMed Melo J. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 1996;88:2375–84.PubMed
25.
go back to reference Schaefer-Rego K, Dudek H, Popenoe D, Arlin Z, Mears JG, Bank A, Leibowitz D. CML patients in blast crisis have breakpoints localized to a specific region of the BCR. Blood. 1987;70(2):448–55.PubMed Schaefer-Rego K, Dudek H, Popenoe D, Arlin Z, Mears JG, Bank A, Leibowitz D. CML patients in blast crisis have breakpoints localized to a specific region of the BCR. Blood. 1987;70(2):448–55.PubMed
26.
go back to reference Eisenberg A, Silver R, Soper L, Arlin Z, Coleman M, Bernhardt B, Benn P. The location of breakpoints within the breakpoint cluster region (bcr) of chromosome 22 in chronic myeloid leukemia. Leukemia. 1988;2:642–7.PubMed Eisenberg A, Silver R, Soper L, Arlin Z, Coleman M, Bernhardt B, Benn P. The location of breakpoints within the breakpoint cluster region (bcr) of chromosome 22 in chronic myeloid leukemia. Leukemia. 1988;2:642–7.PubMed
27.
go back to reference Mills KI, Birnie GD. Prognostic significance of BCR breakpoint location in M-bcr. Leukemia. 1991;5:731–2.PubMed Mills KI, Birnie GD. Prognostic significance of BCR breakpoint location in M-bcr. Leukemia. 1991;5:731–2.PubMed
28.
go back to reference Fioretos T, Heim S, Garwicz S, Ludvigsson J, Mitelman F. Molecular analysis of Philadelphia positive childhood chronic myeloid leukemia. Leukemia. 1992;6:723–5.PubMed Fioretos T, Heim S, Garwicz S, Ludvigsson J, Mitelman F. Molecular analysis of Philadelphia positive childhood chronic myeloid leukemia. Leukemia. 1992;6:723–5.PubMed
29.
go back to reference Zaccaria A, Martinelli G, Buzzi M, Testoni N, Farabegoli P, Zuffa E, Zamagni MD, Russo D, Baccarani M, Ambrosetti A, et al. The type of BCR/ABL junction does not predict the survival of patients with Ph1-positive chronic myeloid leukaemia. Br J Haematol. 1993;84:265–8.PubMedCrossRef Zaccaria A, Martinelli G, Buzzi M, Testoni N, Farabegoli P, Zuffa E, Zamagni MD, Russo D, Baccarani M, Ambrosetti A, et al. The type of BCR/ABL junction does not predict the survival of patients with Ph1-positive chronic myeloid leukaemia. Br J Haematol. 1993;84:265–8.PubMedCrossRef
30.
go back to reference Shepherd P, Suffolk R, Halsey J, Allan N. Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival. Br J Haematol. 1995;89:546–54.PubMedCrossRef Shepherd P, Suffolk R, Halsey J, Allan N. Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival. Br J Haematol. 1995;89:546–54.PubMedCrossRef
31.
go back to reference Branford S, Rudzki Z, Hughes TP. A novel BCR-ABL transcript (e8a2) with the insertion of an inverted sequence of ABL intron 1b in a patient with Philadelphia-positive chronic myeloid leukaemia. Br J Haematol. 2000;109:635–7.PubMedCrossRef Branford S, Rudzki Z, Hughes TP. A novel BCR-ABL transcript (e8a2) with the insertion of an inverted sequence of ABL intron 1b in a patient with Philadelphia-positive chronic myeloid leukaemia. Br J Haematol. 2000;109:635–7.PubMedCrossRef
32.
go back to reference Bennour A, Beaufils N, Sennana H, Meddeb B, Saad A, Gabert J. E355G mutation appearing in a patient with e19a2 chronic myeloid leukaemia resistant to imatinib. J Clin Pathol. 2010;63:737–40.PubMedCrossRef Bennour A, Beaufils N, Sennana H, Meddeb B, Saad A, Gabert J. E355G mutation appearing in a patient with e19a2 chronic myeloid leukaemia resistant to imatinib. J Clin Pathol. 2010;63:737–40.PubMedCrossRef
33.
go back to reference Goh HG, Hwang JY, Kim SH, Lee YH, Kim YL, Kim DW. Comprehensive analysis of BCR-ABL transcript types in Korean CML patients using a newly developed multiplex RT-PCR. Transl Res. 2006;148:249–56.PubMedCrossRef Goh HG, Hwang JY, Kim SH, Lee YH, Kim YL, Kim DW. Comprehensive analysis of BCR-ABL transcript types in Korean CML patients using a newly developed multiplex RT-PCR. Transl Res. 2006;148:249–56.PubMedCrossRef
34.
go back to reference Ito T, Tanaka H, Tanaka K, Ito K, Kyo T, Dohy H, et al. Insertion of a genomic fragment of chromosome 19 between BCR intron 19 and ABL intron 1a in a chronic myeloid leukaemia patient with—BCR-ABL (e19a2) transcript. Br J Haematol. 2004;126:750–5.CrossRef Ito T, Tanaka H, Tanaka K, Ito K, Kyo T, Dohy H, et al. Insertion of a genomic fragment of chromosome 19 between BCR intron 19 and ABL intron 1a in a chronic myeloid leukaemia patient with—BCR-ABL (e19a2) transcript. Br J Haematol. 2004;126:750–5.CrossRef
35.
go back to reference Reiter E, Greinix HT, Brugger S, Keil F, Rabitsch W, Mannhalter C, et al. Long-term follow-up after allogeneic stem cell transplantation for chronic myelogenous leukemia. Bone Marrow Transp. 1998;22(supp 14):S86–8. Reiter E, Greinix HT, Brugger S, Keil F, Rabitsch W, Mannhalter C, et al. Long-term follow-up after allogeneic stem cell transplantation for chronic myelogenous leukemia. Bone Marrow Transp. 1998;22(supp 14):S86–8.
36.
go back to reference Udomsakdi-Auewarakul C, U-Pratya Y, Boonmoh S, Vatanavicharn S. Detection of molecular variants of BCR-ABL gene in bone marrow and blood of patients with chronic myeloid leukemia by reverse-transcriptase polymerase chain reaction (RT-PCR). J Med Assoc Thai. 2000;83:928–35.PubMed Udomsakdi-Auewarakul C, U-Pratya Y, Boonmoh S, Vatanavicharn S. Detection of molecular variants of BCR-ABL gene in bone marrow and blood of patients with chronic myeloid leukemia by reverse-transcriptase polymerase chain reaction (RT-PCR). J Med Assoc Thai. 2000;83:928–35.PubMed
37.
go back to reference Yaghmaie M, Ghaffari SH, Ghavamzadeh A, Alimoghaddam K, Jahani M, Mousavi SA, Irvani M, Bahar B, Bibordi I. Frequency of BCR-ABL Fusion transcripts in Iranian patients with Chronic Myeloid Leukemia. Arch Iran Med. 2008;11:247–51.PubMed Yaghmaie M, Ghaffari SH, Ghavamzadeh A, Alimoghaddam K, Jahani M, Mousavi SA, Irvani M, Bahar B, Bibordi I. Frequency of BCR-ABL Fusion transcripts in Iranian patients with Chronic Myeloid Leukemia. Arch Iran Med. 2008;11:247–51.PubMed
38.
go back to reference Lee MS, LeMaistre A, Kantarjian HM, Talpaz M, Freireich EJ, Trujillo JM, Stass SA. Detection of two alternative bcr/abl mRNA junctions and minimal residual disease in Philadelphia chromosome positive chronic myelogenous leukemia by polymerase chain reaction. Blood. 1989;73:2165–70.PubMed Lee MS, LeMaistre A, Kantarjian HM, Talpaz M, Freireich EJ, Trujillo JM, Stass SA. Detection of two alternative bcr/abl mRNA junctions and minimal residual disease in Philadelphia chromosome positive chronic myelogenous leukemia by polymerase chain reaction. Blood. 1989;73:2165–70.PubMed
39.
go back to reference Arana-Trejo RM, Ruiz Sanchez E, Ignacio-Ibarra G, de la Baez Fuente E, Garces O, Gomez Morales E, Arana-Trejo RM, Castro Granados M, Ovilla Martinez R, Rubio-Borja ME, Solis Anaya L, et al. BCR/ABL p210, p190 and p230 fusion genes in 250 Mexican patients with chronic myeloid leukaemia (CML). Clin Lab Haematol. 2002;24:145–50.PubMedCrossRef Arana-Trejo RM, Ruiz Sanchez E, Ignacio-Ibarra G, de la Baez Fuente E, Garces O, Gomez Morales E, Arana-Trejo RM, Castro Granados M, Ovilla Martinez R, Rubio-Borja ME, Solis Anaya L, et al. BCR/ABL p210, p190 and p230 fusion genes in 250 Mexican patients with chronic myeloid leukaemia (CML). Clin Lab Haematol. 2002;24:145–50.PubMedCrossRef
40.
go back to reference Henegariu O, Heerema NA, Dlouhy SR, Vance GH, Vogt PH. Multiplex PCR: critical parameters and step-by-step protocol. Biotechniques. 1997;23:504–11.PubMed Henegariu O, Heerema NA, Dlouhy SR, Vance GH, Vogt PH. Multiplex PCR: critical parameters and step-by-step protocol. Biotechniques. 1997;23:504–11.PubMed
41.
go back to reference Sastre D, Argaraña C, Heller V, Gallo M, EnFernández E, Rodríguez C. An analysis of multiplex-PCR in the detection of BCR-ABL transcripts in hematological disorders. Genet Mol Biol. 2007;30:520–3.CrossRef Sastre D, Argaraña C, Heller V, Gallo M, EnFernández E, Rodríguez C. An analysis of multiplex-PCR in the detection of BCR-ABL transcripts in hematological disorders. Genet Mol Biol. 2007;30:520–3.CrossRef
42.
go back to reference Marcelle C, Gale RP, Prokocimer M, Berrebe A, Merle Beral H, Canani E. Analysis of BCR-ABL mRNA in chronic myelogenous leukemia patients and identification of a new BCR-Related sequence in human DNA. Genes Chromosomes Cancer. 1989;1:172–9.PubMedCrossRef Marcelle C, Gale RP, Prokocimer M, Berrebe A, Merle Beral H, Canani E. Analysis of BCR-ABL mRNA in chronic myelogenous leukemia patients and identification of a new BCR-Related sequence in human DNA. Genes Chromosomes Cancer. 1989;1:172–9.PubMedCrossRef
43.
go back to reference Elliott SL, Taylor KM, Taylor DL, Rodwell RL, Williams BF, Shuttlewood MM, Wright SJ, Eliadist PE, Bunce IH, Frost TJ, Olsen TE, Firkin F, Timms P. Cytogenetic response to alpha-interferon is predicted in early chronic phase chronic myeloid leukemia by M-bcr breakpoint location. Leukemia. 1995;9:946.PubMed Elliott SL, Taylor KM, Taylor DL, Rodwell RL, Williams BF, Shuttlewood MM, Wright SJ, Eliadist PE, Bunce IH, Frost TJ, Olsen TE, Firkin F, Timms P. Cytogenetic response to alpha-interferon is predicted in early chronic phase chronic myeloid leukemia by M-bcr breakpoint location. Leukemia. 1995;9:946.PubMed
44.
go back to reference Jaubert J, Martiat P, Dowding C, Ifrah N, Goldman J. The position of the M-BCR breakpoint does not predict the duration of chronic phase or survival in chronic myeloid leukaemia. Br J Haematol. 1990;74:30–5.PubMedCrossRef Jaubert J, Martiat P, Dowding C, Ifrah N, Goldman J. The position of the M-BCR breakpoint does not predict the duration of chronic phase or survival in chronic myeloid leukaemia. Br J Haematol. 1990;74:30–5.PubMedCrossRef
45.
go back to reference Morris SW, Daniel L, Ahmed CM, Elias A, Lebowitz P. Relationship of bcr breakpoint to chronic phase duration, survival, and blast crisis lineage in chronic myelogenous leukemia patients presenting in early chronic phase. Blood. 1990;75:2035–41.PubMed Morris SW, Daniel L, Ahmed CM, Elias A, Lebowitz P. Relationship of bcr breakpoint to chronic phase duration, survival, and blast crisis lineage in chronic myelogenous leukemia patients presenting in early chronic phase. Blood. 1990;75:2035–41.PubMed
46.
go back to reference Martínez-Mancilla M, Gutiérrez M, de la Rosa GZ, García-Carrancá A, Gariglio P, Miranda E. Younger age and shorter chronic phase in b2a2-positive chronic myeloid leukemia adults with high white blood cell count at diagnosis. Haematologica. 2002;87:666–8.PubMed Martínez-Mancilla M, Gutiérrez M, de la Rosa GZ, García-Carrancá A, Gariglio P, Miranda E. Younger age and shorter chronic phase in b2a2-positive chronic myeloid leukemia adults with high white blood cell count at diagnosis. Haematologica. 2002;87:666–8.PubMed
47.
go back to reference Cervantes F, Colomer D, Vives-Corrons JL, Rozman C, Montserrat E. Chronic myeloid leukemia of thrombocythemic onset: a CML subtype with distinct hematological and molecular features? Leukemia. 1996;10:1241–3.PubMed Cervantes F, Colomer D, Vives-Corrons JL, Rozman C, Montserrat E. Chronic myeloid leukemia of thrombocythemic onset: a CML subtype with distinct hematological and molecular features? Leukemia. 1996;10:1241–3.PubMed
48.
go back to reference Blickstein D, Aviram A, Luboshitz J, Prokocimer M, Stark P, Bairey O, Sulkes J, Shaklai M. BCR-ABL transcripts in bone marrow aspirates of Philadelphia-negative essential thrombocytopenia patients: clinical presentation. Blood. 1997;90:2768–71.PubMed Blickstein D, Aviram A, Luboshitz J, Prokocimer M, Stark P, Bairey O, Sulkes J, Shaklai M. BCR-ABL transcripts in bone marrow aspirates of Philadelphia-negative essential thrombocytopenia patients: clinical presentation. Blood. 1997;90:2768–71.PubMed
49.
go back to reference Verstovsek S, Lin H, Kantarjian H, Saglio G, De Micheli D, Pane F, Garcia-Manero G, Intrieri M, Rotoli B, Salvatore F, Guo JQ, Talpaz M, Specchia G, Pizzolo G, Liberati AM, Cortes J, Quackenbush RC, Arlinghaus RB. Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course. Cancer. 2002;94:2416–25.PubMedCrossRef Verstovsek S, Lin H, Kantarjian H, Saglio G, De Micheli D, Pane F, Garcia-Manero G, Intrieri M, Rotoli B, Salvatore F, Guo JQ, Talpaz M, Specchia G, Pizzolo G, Liberati AM, Cortes J, Quackenbush RC, Arlinghaus RB. Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course. Cancer. 2002;94:2416–25.PubMedCrossRef
Metadata
Title
Analysis of the clinico-hematological relevance of the breakpoint location within M-BCR in chronic myeloid leukemia
Authors
Ayda Bennour
Ines Ouahchi
Bechir Achour
Monia Zaier
Yosra Ben Youssef
Abderrahim Khelif
Ali Saad
Halima Sennana
Publication date
01-03-2013
Publisher
Springer US
Published in
Medical Oncology / Issue 1/2013
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-012-0348-z

Other articles of this Issue 1/2013

Medical Oncology 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.